SAB Biotherapeutics, Inc. (SABS): Nasdaq/NYSE listing notice — SAB Biotherapeutics receives Nasdaq minimum bid price deficiency notice

SAB Biotherapeutics, Inc.

Received Nasdaq notice on Jan 23, 2023; common stock bid price below $1.00 for 30 consecutive business days.
Has 180 calendar days (until July 24, 2023) to regain compliance by closing bid price >= $1.00 for 10 consecutive days.
If not compliant, may apply for additional 180-day period; reverse stock split is a potential cure.
No immediate effect on listing; company monitoring and evaluating options to regain compliance.
Failure to regain compliance could lead to delisting from the Nasdaq Global Market.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

SAB Biotherapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5450(a)(1)

Exact text from the filing

January 23, 2023, SAB Biotherapeutics, Inc. (the "Company") received a written notification (the “Notice Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that we were not in compliance with Nasdaq Listing Rule 5450(a)(1), as the closing bid price for our common stock was below the $1.00 per share requirement for the last 30 consecutive business days. The Notice Letter stated that we have 180 calendar days, or until July 24, 2023 (the “Initial Compliance Period”), to regain compliance with the minimum bid price requirement. If we do not regain compliance by the end of

View on SEC.gov

Browse all listing & compliance notices →

SAB Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-001990

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.